In the first phase of the three-part pilot program, three projects will be chosen from 10 institutions in the Philadelphia region, Delaware, and New Jersey to receive one-year grants worth as much as $200,000 for proof-of-concept studies.
DNAPrint, Laboratory Corporation of America, Duke University, Lab21, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Diseases and Stroke, and more …
Cerenis, Montreal Heart Institute, UVA, Ortho Clinical, Mirna, UCSF, Case Western, Diagnostic Hybrids, iBridge Network, Ben Franklin Tech Partners, and more…
